{"id":"W2513452411","doi":"10.1002/acn3.338","title":"Alpha‐synuclein <scp>RT</scp>‐Qu<scp>IC</scp> in the <scp>CSF</scp> of patients with alpha‐synucleinopathies","year":2016,"lang":"en","type":"article","venue":"Annals of Clinical and Translational Neurology","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":613,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Medical Research Council; Otsuka Pharmaceutical Development and Commercialization; Scottish Office Home and Health Department; NIHR Oxford Biomedical Research Centre; University of Oxford; Parkinson's UK; Michael J. Fox Foundation for Parkinson's Research; Department of Health and Social Care; National Institute for Health and Care Research; Alzheimer Society; Scottish Government","keywords":"Synucleinopathies; Medicine; Alpha (finance); Alpha-synuclein; Internal medicine; Parkinson's disease; Disease","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05470338086853653,"score_gpt":0.3292634768866052,"score_spread":0.2745600960180686,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}